Bausch Health Companies Inc. Accounts Receivable, Allowance for Credit Loss, Writeoff
Bausch Health Companies Inc. (BHC) reported Accounts Receivable, Allowance for Credit Loss, Writeoff of $2.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs · last filed 2026-07-30
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2026-06-30 was $2.00M, a 66.67% decline year-over-year.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2026-03-31 was $0.00.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2025-12-31 was $1.00M, a 0.00% change year-over-year.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for fiscal 2025 was $7.00M, a 75.00% increase from fiscal 2024.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for fiscal 2024 was $4.00M, a 20.00% decline from fiscal 2023.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for fiscal 2023 was $5.00M, a 16.67% decline from fiscal 2022.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, writeoff for fiscal 2022 was $6.00M, a 100.00% increase from fiscal 2021.
| Period end | Accounts Receivable, Allowance for Credit Loss, Writeoff 3 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 6 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 9 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.00M 10-Q · filed 2026-07-30 | $3.00M derived: sum of 3 quarters · filed 2026-07-30 | $3.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $1.00M derived: sum of 2 quarters · filed 2026-04-30 | $1.00M derived: sum of 3 quarters · filed 2026-04-30 | $7.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.00M derived: sum of 2 quarters · filed 2026-02-19 | $7.00M derived: sum of 3 quarters · filed 2026-07-30 | $7.00M 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.00M derived: sum of 2 quarters · filed 2026-07-30 | $6.00M 10-Q · filed 2025-10-30 | $7.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $6.00M 10-Q · filed 2026-07-30 | $7.00M derived: sum of 3 quarters · filed 2026-07-30 | $9.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $1.00M derived: sum of 2 quarters · filed 2026-04-30 | $3.00M derived: sum of 3 quarters · filed 2026-04-30 | $4.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.00M derived: sum of 2 quarters · filed 2026-02-19 | $4.00M derived: sum of 3 quarters · filed 2026-02-19 | $4.00M 10-K · filed 2026-02-19 |
| 2024-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.00M derived: sum of 2 quarters · filed 2025-10-30 | $3.00M 10-Q · filed 2025-10-30 | $5.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.00M 10-Q · filed 2025-07-31 | $3.00M derived: sum of 3 quarters · filed 2026-02-19 | $4.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $2.00M derived: sum of 2 quarters · filed 2026-02-19 | $3.00M derived: sum of 3 quarters · filed 2026-02-19 | $4.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.00M derived: sum of 2 quarters · filed 2026-02-19 | $4.00M derived: sum of 3 quarters · filed 2026-02-19 | $5.00M 10-K · filed 2026-02-19 |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.00M derived: sum of 2 quarters · filed 2024-10-31 | $3.00M 10-Q · filed 2024-10-31 | $9.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.00M 10-Q · filed 2024-08-01 | $8.00M derived: sum of 3 quarters · filed 2025-02-20 | $7.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-02 | $7.00M derived: sum of 2 quarters · filed 2025-02-20 | $6.00M derived: sum of 3 quarters · filed 2025-02-20 | $7.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $5.00M derived: sum of 2 quarters · filed 2025-02-20 | $6.00M derived: sum of 3 quarters · filed 2025-02-20 | $6.00M 10-K · filed 2025-02-20 |
| 2022-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.00M 10-Q · filed 2023-08-03 | $1.00M derived: sum of 3 quarters · filed 2024-02-22 | $3.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $2.00M derived: sum of 3 quarters · filed 2024-02-22 | $2.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.00M derived: sum of 2 quarters · filed 2024-02-22 | $2.00M derived: sum of 3 quarters · filed 2024-02-22 | $3.00M 10-K · filed 2024-02-22 |
| 2021-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.00M derived: sum of 2 quarters · filed 2022-11-03 | $3.00M 10-Q · filed 2022-11-03 | $12.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.00M 10-Q · filed 2022-08-09 | $10.00M derived: sum of 3 quarters · filed 2023-02-23 | $11.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-10 | $10.00M derived: sum of 2 quarters · filed 2023-02-23 | $11.00M derived: sum of 3 quarters · filed 2023-02-23 | $13.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $10.00M derived: sum of 2 quarters · filed 2023-02-23 | $12.00M derived: sum of 3 quarters · filed 2023-02-23 | $12.00M 10-K · filed 2023-02-23 |
| 2020-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $3.00M derived: sum of 2 quarters · filed 2021-11-02 | $3.00M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $2.00M 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $10.00M 8-K · filed 2022-05-11 | |||
| 2018-12-31 | $50.00M 8-K · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |